Also (says maybe):
Debunking myth 2: Increased risk of tumor growth
Do GH secretagogues like CJC/ipamorelin increase tumor growth risks? There’s no definitive link between such peptides and tumor growth.
These secretagogues indirectly stimulate GH and IGF-1 release. Some tumour cell types have IGF receptors. Their mechanisms aren’t entirely understood. Still, the risk of secondary tumor growth is minimal compared to other cancer risk factors.
Higher IGF-1 levels are associated with both an increased and decreased risk of certain cancer types. Researchers can’t definitively explain why. And reverse causality (where cancer would elevate IGF-1 levels) isn’t ruled out.
More long-term studies in humans are needed.
Cancer development is a multifaceted process. Genetic predispositions, environmental factors, and nutritional variables all impact it. As such, tumor growth can’t be attributed solely to peptide therapies like CJC/ipamorelin.